SCHEMBL31435973

SCHEMBL31435973

COc1nn(C2CCN(C)CC2)cc1-c1cnc2c(c1)c(-c1cccc(F)c1)c(Cl)n2S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.35
DRD2 P14416 1/20 0.35
SLC6A2 P23975 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR7 P34969 1/20 0.35
HRH1 P35367 1/20 0.35
ADRA1B P35368 1/20 0.35
SLC6A3 Q01959 1/20 0.35
EIF2AK3 Q9NZJ5 1/20 0.34
HTR6 P50406 2/20 0.33
CHRM3 P20309 2/20 0.33
ACVR1 Q04771 1/20 0.33
KDM2B Q8NHM5 1/20 0.32
SCN9A Q15858 1/20 0.32
PIM1 P11309 1/20 0.32
PIM2 Q9P1W9 1/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31435969 0.92 MAP4K3 (0.38) EIF2AK3HTR6SCN9APIM1PIM2
SCHEMBL31436018 0.90 CHRM3 (0.34) CYP3A4DRD2SLC6A2HTR2AHTR2C
SCHEMBL31435916 0.86 PTPN11 (0.40) CYP3A4DRD2SLC6A2HTR2AHTR2C
SCHEMBL31435978 0.83 PTPN11 (0.39) CYP3A4DRD2SLC6A2HTR2AHTR2C
SCHEMBL31435911 0.83 JAK2 (0.35) CYP3A4DRD2SLC6A2HTR2AHTR2C
SCHEMBL31435972 0.83 ELANE (0.32) ACVR1AXLMTOR
SCHEMBL31436005 0.82 MAP4K3 (0.37) DRD2HTR7EIF2AK3HTR6PIM1
SCHEMBL31435983 0.82 PTPN11 (0.40) CYP3A4DRD2SLC6A2HTR2AHTR2C
SCHEMBL31435940 0.82 MET (0.35) HTR6CHRM3ACVR1KDM2BJAK2
SCHEMBL30365472 0.79 PTPN11 (0.38) CYP3A4DRD2SLC6A2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2025-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS TYRO3, TH, TYR CYP3A4 776/4885DRD2 2348/4885SLC6A2 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.